All
Improving Treatment Access to Innovative Therapies in Breast Cancer
Dr. Maxwell Lloyd shared the importance of improving patient access to innovative therapies like Orserdu at the 2024 San Antonio Breast Cancer Symposium.
FDA Approves Lumakras with Vectibix in KRAS G12C+ Colorectal Cancer
The FDA has approved Lumakras with Vectibix for adults with KRAS G12C-mutated metastatic colorectal cancer who received chemotherapy.
FDA Approves Calquence Combo for Mantle Cell Lymphoma
The Food and Drug Administration has granted traditional approval to Calquence with bendamustine and Rituxan for some patients with MCL.
An Expert Breaks Down the Meaning of MRD Testing in Cancer Care
Dr. Christopher R. Flowers delved into the meaning of MRD, discussing different ways that it may be tested for in patients with various types of cancer.
Diet Plus Fish Oil May Reduce Ki-67 Biomarkers in Prostate Cancer
A diet high in omega-3 fatty acids and low in omega-6 fatty acids, taken with fish oil, reduced the Ki-67 index in men with prostate cancer on active surveillance.
Honoring the Memory of Surviving After Cancer
Fifteen years after my own cancer journey, I find myself balancing hope and grief as I support a colleague newly diagnosed with cancer.
Angie’s Impact Story: No Longer in the Shadows – Spreading Awareness About Metastatic Breast Cancer
In February 2016, Angie was diagnosed with de novo metastatic breast cancer after experiencing back and rib pain.
ABCD Has Inspired Hope and Transformed Lives For 25 Years Through Its Customized Emotional Support for Anyone Impacted by Breast Cancer
In 1992, Milwaukee broadcast journalist Melodie Wilson Oldenburg announced on live television she had been diagnosed with breast cancer.
Surgery May Extend Survival For Patients with GIST and Liver Metastases
For patients with gastrointestinal stromal tumors with liver metastases, treatment with surgery and chemotherapy has been found to have survival benefits.
HT-001 Addresses Skin Toxicities in Patients With Cancer
In patients with cancer, HT-001, designed to address skin toxicities, elicited encouraging interim safety and efficacy results in the CLEER-001 trial
The Subcutaneous Approval of Opdivo Makes Waves in Future of Cancer Care
Subcutaneous Opdivo improves cancer care by offering faster, accessible therapy, reducing time toxicity and expanding patient access, according to experts.
Most Cures to Cancer Shared on TikTok Are Fake, Research Shows
Findings show that 81% of posts related to cancer on the social media platform TikTok touted fake cures.
Finding Strength Through Faith and Positivity During Cancer
I share how faith, positive affirmations and resilience helped me overcome stage 2 colon cancer and find strength in recovery.
Machine Learning Predicts Gleevec Nonadherence in Patients With GIST
Indicators for Gleevec nonadherence were cognitive functioning, global health status score, social support, gender and others in patients with GIST.
Elinzanetant May Treat Hot Flashes Caused by Breast Cancer Treatment
Elinzanetant significantly reduced the frequency and severity of hot flashes in women with breast cancer who were undergoing hormone therapy.
FDA Grants Priority Review to Sunvozertinib for EGFR Exon20+ NSCLC
The Food and Drug Administration has accepted and granted priority review to a new drug application for sunvozertinib.
Expert Expands on Side Effects Related to ADC Treatment in Breast Cancer
Dr. Aditya Bardia shared his insights on what he believes are the top side effects to be aware of when undergoing ADC treatment for breast cancer.
The Waiting Room: An Underappreciated Experience
As a cancer treatment waiting room volunteer, I’ve discovered a unique community of shared experiences and unexpected connections.
The Pros and Cons of Seeking a Second Opinion In Cancer Treatment
An expert explains the importance of getting a second opinion during a cancer journey.
Fixed-Dose Subcutaneous Sarclisa Combo is Non-Inferior to IV Sarclisa in R/R Myeloma
Treatment with fixed-dose subcutaneous Sarclisa plus Pomalyst and dexamethasone was non-inferior to IV Sarclisa in relapsed/refractory multiple myeloma.
Sasanlimab Improves Event-Free Survival for Some With Bladder Cancer
The investigational anti-PD-1 monoclonal antibody is showing positive topline results from the phase 3 CREST trial.
Delving into Subcutaneous Versus Intravenous Opdivo in Solid Tumors
Dr. Balazs Halmos discusses the significance of the FDA approval of the subcutaneous injection formulation of Opdivo for patients with solid tumors.
Always Bring a Second Set of Ears to Your Oncology Checkup!
At my routine oncology checkup, I regretted not bringing my husband when an unexpected medication changes left me feeling overwhelmed and alone.
HIPEC May Not Improve Outcomes for Recurrent Epithelial Ovarian Cancer
Adding hyperthermic intraperitoneal chemotherapy to surgery did not improve progression-free survival in platinum-sensitive recurrent ovarian cancer.
SBRT May Be a Viable Option for Patients With Liver Cancer
CURE spoke with an expert about the potential positive effects of radiation therapy for patients with hepatocellular carcinoma.
The Gift of a Second Chance After My Stem Cell Transplant
After experiencing unexplained symptoms, I was diagnosed with multiple myeloma and underwent a stem cell transplant.
FDA Grants Fast Track Designation for Abenacianine in Lung Cancer Surgery
The FDA has granted fast track designation for abenacianine to help surgeons better visualize lung tumors during minimally invasive surgery.
A Breakdown of Trial Data that Led to the Subcutaneous Opdivo FDA Approval
Dr. Eric K. Singhi discusses the significance of the FDA approval of subcutaneous Opdivo for patients with solid tumors.
The Impact of Yescarta on Long Term Quality of Life in R/R Follicular Lymphoma
Dr. Sattva S. Neelapu discusses how the CAR-T therapy Yescarta impacts the quality of life of patients with R/R indolent non-Hodgkin lymphoma.
P1101 Treatment Meets Phase 3 Primary End Point in Essential Thrombocythemia
P1101 had durable hematologic responses and manageable safety among patients with essential thrombocythemia, meeting the primary end goal of SURPASS-ET.
